Inbox Simulation Analysis

Words: 1375
Pages: 6

During the Inbox simulation, you will play the role of Chris Hendricks, a newly appointed District Sales Manager for District 1 in the Atlanta Region of the Vega Pharmaceuticals organization. The date is Monday, July 17, 20XX.
The regional office is in Roswell, GA, a suburb of Atlanta. You manage a team of eight Sales Representatives. You report to Diane Alonzo, Regional Director, Atlanta Region, who works out of Vega Pharmaceutical’s regional office in Atlanta.
Your predecessor, George Radecki, has left for his new special and urgent assignment with Vega Pharmaceuticals in London. Over the last three months, he has been getting ready for his special project while continuing to function as the District Sales Manager for the district. However,
…show more content…
He will not be settled into his new office until next week. Therefore, you will not be able to discuss any issues or problems with him at this time.
INSTRUCTIONS
Because there will be no other opportunities to address the emails, you need to make as much progress as possible during the simulation. Work through the emails in any way you wish and take whatever action you think appropriate. Keep in mind that your ideas and actions cannot be evaluated unless you clearly record them. Some considerations:
 Write every action you take, including notes to sales professionals, institutional and national, and regional account managers, yourself, and others.
 Do not just say what you would do in each situation, but actually write out emails where
…show more content…
We have always found visits by your representatives to be informative and valuable. However, as an HMO in a large metropolitan area, we find ourselves inundated by representatives from many different pharmaceutical and medical product companies. We recently instituted a sign-in process to more effectively track such visitors at our facility, and were surprised to find so many different representatives from the same companies were calling on our physicians. Vega Pharmaceuticals is one of those companies. Last month alone, we were visited on thirteen occasions by Vega Pharmaceuticals staff who said they were from Specialties, Managed Markets, Generics, etc. I'm sure you can understand that we must protect the valuable time of our physicians and other staff. Consequently, we will begin restricting the number of visits from our vendors.
I want to assure you that this letter is going to many of your competitors, as well, and should not be interpreted to mean that we are dissatisfied with you specifically. Rather, we are simply interested in making contacts between Covenant staff and our vendors as efficient as possible. We believe that it's not in our best interest to be seeing more than one representative from our various